Find latest Breast videos · 400+ videos
Fred Hutchinson Cancer Center
N

Biology and Clinical Relevance of ESR1 Mutation in Breast Cancer

By Fred Hutchinson Cancer Center FEATURING Nancy Davidson
By Fred Hutchinson Cancer Center FEATURING Nancy Davidson
248 views
August 2, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

05:15
Lilly Medical Affairs

Unmet Needs for Patients With HR+, HER2- Early Breast Cancer at a Hi…

Feat. H. Rugo

Featured Video

06:40
Lilly Medical Affairs

Communicating the Risk of Recurrence for Patients With HR+, HER2- Ea…

Feat. J. O’Shaughnessy

Related Videos

25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

4.3K views
06:39

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

731 views
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.2K views
06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
10:53

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.3K views
06:51

SABCS 2024 Noteworthy Abstracts in Metastatic Breast Cancer

Sara Tolaney

H. Rugo

546 views
17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.6K views
15:57

SABCS 2024 Noteworthy Abstracts in Early Breast Cancer

Sara Tolaney

H. Rugo

618 views
14:52

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

842 views
03:15
Lilly Medical Affairs

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

Feat. W. Mchayleh
02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
38:49

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

586 views
20:32

ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Bre…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

556 views
09:12

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, …

2024 ESMO Annual Meeting Insights Hub

V. Kaklamani

539 views
12:38

NATALEE Trial Impact on eBC: Ribociclib + ET as Adjuvant Treatment i…

Jan-Willem Henning

487 views
20:25

ESMO 2024 Summary: Highlights in mBC

2024 ESMO Annual Meeting Insights Hub

G. Bianchini

533 views
07:23

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

1.4K views
03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri
AUTOPLAY